Navigation Links
Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 27, 2007 - Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced positive results from a recently-completed multi-dose pharmacokinetic study of vaginally-administered lidocaine, which the Company is developing to prevent and treat dysmenorrhea.

This 42-subject study was designed to provide data on blood levels associated with the Company's bioadhesive vaginal lidocaine formulation at three dose strengths over multiple doses. The cohort was randomly divided into three groups, which corresponded to the three different dose strengths of the lidocaine product candidate.

"For each of the dose levels studied, use of our bioadhesive vaginal lidocaine formulation over four consecutive days was associated with blood levels that are well within an accepted range," stated George Creasy, M.D., FACOG, Columbia's vice president of clinical research and development. "At the highest dose, those blood levels are what we anticipated based on extrapolation of data from the prior, single-administration pharmacokinetic study. This indicates a positive safety profile for our lidocaine product candidate relative to the known systemic effects of lidocaine."

"This positive data strengthens our resolve to speed the path to market for our lidocaine product. We received approval from the Institutional Review Board to conduct a Phase II cross-over study with this drug candidate and we will begin recruiting patients in this study very soon," stated Robert S. Mills, president and chief executive officer of Columbia Laboratories. "There are approximately 5.6 million women who suffer from the painful menstrual cramping that characterizes dysmenorrhea, which limits their normal activities and causes them to lose time from school or work. We believe our lidocaine product can fill a real unmet medical need and improve the lives of these women, assuming positive data in current and future c
'"/>




Page: 1 2 3

Related medicine technology :

1. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
2. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
3. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
5. Northfield Laboratories Investor Update
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:9/18/2014)... , Sept. 18, 2014   3D Systems   ... the Simbionix RobotiX Mentor™ , a new robotic surgery ... the first time at the ERUS exhibition in ... (booth #7). Robotic-assisted minimally invasive surgery represents a ... means the needs for training for robotic surgery has increased, ...
(Date:9/18/2014)... After 6 months of careful research ... - the new programme for the next Cool Chain & ... global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and purchasing ... is broad and yet specific, focused and yet accessible, inclusive ...
(Date:9/18/2014)... new expert panel report, Improving Medicines for Children ... by the Council of Canadian Academies, addresses the importance ... year about half of Canada,s ... Much of this prescribing is done off-label (i.e. the ... risks. Children have historically been excluded in ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
... Sept. 10 National Jewish Health and,Roche ... to pursue,opportunities in the growing field of ... expertise in clinical testing,and care for patients ... technology to bring new diagnostic solutions to,the ...
... September 10 Circassia Ltd, a,specialty biopharmaceutical ... announced positive results from a phase II ... the field of cat allergy.,The trial showed ... to the allergen that causes most cat ...
Cached Medicine Technology:National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities 2Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology 2Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology 3
(Date:9/18/2014)... Park City, Utah (PRWEB) September 19, 2014 ... Solution, published new information on why to switch employees ... Benefits, though many employees may be more familiar with ... individual health insurance that makes employees happier. , ... employees are happier with individual health insurance rather than ...
(Date:9/18/2014)... Mary Ann Thompson and Mathieu Nikel decided it was time to ... their son, Isaac, said there was only one choice for them ... 2001 when Thompson was an undergraduate student and needed a French ... time, was French and so she asked him. , ... when she was 7 years old. Nikel is originally from ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Active Aging ... and older as fully participating members of society and ... To celebrate, The Stafford – a boutique retirement community ... – will host two screenings of Cyber-Seniors - a ... for our residents to watch this great film,” says ...
(Date:9/18/2014)... world have issued a plea to researchers, academics, drug ... research and clinical trials for advanced breast cancer, a ... there are many unanswered questions. , In the latest ... cancer, published simultaneously in the leading cancer journals ... [1] today (Friday), the experts say that further research ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Memorial ... made history this week by performing the first ever, ... UNOS (United Network for Organ Sharing) approval to launch ... one of only two programs in South Florida. ... Dr. Enrique Gongora, Medical Director of the ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Why Employees Are Happier with Individual Health Insurance 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2Health News:Experts issue plea for better research and education for advanced breast cancer 2Health News:Experts issue plea for better research and education for advanced breast cancer 3Health News:Experts issue plea for better research and education for advanced breast cancer 4Health News:Experts issue plea for better research and education for advanced breast cancer 5Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4
... Reporter , MONDAY, Dec. 5 (HealthDay News) -- Eating ... salmon, may significantly lower a young woman,s risk of ... that women of childbearing age who never ate fish had ... often, and a 90 percent higher risk than women who ...
... has seen a dramatic increase in the presence of ... the stigmatized stereotype of gays into a new, socially ... marketing strategy affects the way gays understand themselves and ... explains Wan-Hsiu Sunny Tsai, assistant professor of advertising at ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... epilepsy drug valproate have a nearly three times higher ... finds. Researchers in Denmark used national birth data ... between 1996 and 2006 to 428,000 women. Using a ...
... , MONDAY, Dec. 5 (HealthDay News) -- A ... in the teenage brain. The research found that teens who,ve ... contains brain cells -- in some areas of the brain ... involved in the study had a history of abuse or neglect. ...
... Ky. -- University of Kentucky researchers recently received a ... in Appalachia. The grant gives the team $225,000 ... additional years that could total $675,000. It is funded ... the UK-based Rural Cancer Prevention Center. Published studies ...
... Respirology reveals that dust storms have an adverse ... known as chronic obstructive pulmonary disease (COPD). Dust storms ... dust that travels long distances from North China. The concentrations ... 10 micrometerscan reach very high levels. Researchers led by ...
Cached Medicine News:Health News:Fish May Cut Threat of Heart Disease in Young Women 2Health News:Fish May Cut Threat of Heart Disease in Young Women 3Health News:How advertising shapes the image of gayness in America 2Health News:Fetal Exposure to Epilepsy Drug Might Raise Autism Risk: Study 2Health News:Fetal Exposure to Epilepsy Drug Might Raise Autism Risk: Study 3Health News:Abuse in Childhood May Alter Teen Brain 2Health News:University of Kentucky researchers awarded CDC grant to study cancer survival in Appalachia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: